- INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient.
- INKmune approach will be used to activate dormant NK cells and allow them to kill off cancer cells; additional indications include ovarian cancer, renal cell carcinoma and nasopharyngeal carcinoma.
- XPro is in a phase 2 study for the treatment of mild Alzheimer's Disease patients; Results from this study expected by 2nd half of 2023.
- The global Alzheimer's Disease market could reach $25 billion by 2027.
For further details see:
INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors